← Back

Wire · opportunities

Spatial biomarker to companion diagnostic

Published

19 August 2026

Topic

opportunities

Sectors

Diagnostics

Source

Read at drugdiscoverynews.com

Verified

Fusion42 · 19 August 2026 · Fusion42 review

The article details the development path of spatial biomarkers into companion diagnostics, emphasizing the importance of assay standardization, analytical and clinical validation, and multi-site reproducibility for reliable clinical use.

This Wire brief sits within Fusion42's coverage of Diagnostics.

◆ The Wire takeaway

You now need to fix and thoroughly validate your assay parameters to move beyond research into clinical diagnostics reliably. This means locking down your protocol early to avoid costly setbacks and proving reproducibility across different labs.

Coverage

1 source · 19 Aug 2026

Related on Wire

Topics

Diagnosticsspatial-biomarkercompanion-diagnosticassay-validationclinical-trialsreproducibility